Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Last trade$3.17
Day change+$0.10 (+3.26%)
Day range$3.05 – $3.19
Volume2,379,912
Market cap$772M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$771.71M
Price / earnings
—
Price / book
4.7×
Price / sales
1.65×
EV / sales
2.09×
EV / EBITDA
-29.6×
Profitability
Earnings per share
-$0.22
Return on assets
-9.44%
Return on equity
-33.81%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.54×
Current ratio
3.45×
Quick ratio
3.26×
Cash ratio
0.36×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.96M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ARDX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$127.66M
$120.88M
$94.47M
$125.22M
$110.33M
$97.66M
$74.11M
$116.13M
Cost of revenue
$4.54M
$5.76M
$4.81M
$10.85M
$3.98M
$12.4M
$12.3M
$18.26M
Gross profit
$123.12M
$115.12M
$89.66M
$114.37M
$106.35M
$85.26M
$61.81M
$97.87M
Selling, general and administrative
$93.89M
$101.44M
$102.27M
$86.41M
$83.61M
$83.99M
$83.22M
$76.07M
Research and development
$25.2M
$26.1M
$20.19M
$22.86M
$18.07M
$15.67M
$14.94M
$13.67M
Total operating expenses
$119.09M
$127.54M
$122.46M
$109.27M
$101.68M
$99.65M
$98.16M
$89.74M
Operating income
$4.02M
-$12.43M
-$32.79M
$5.1M
$4.67M
-$14.4M
-$36.35M
$8.13M
Interest expense
-$7.38M
-$6.22M
-$6.92M
$719K
-$7.98M
-$6.58M
-$6.26M
$1.24M
Income before taxes
-$647K
-$16.61M
-$37.6M
-$400K
-$867K
-$19.08M
-$40.29M
$4.68M
Income taxes
$90K
$110K
$8K
$7K
$102K
$1K
$859K
$35K
Net income
-$737K
-$16.72M
-$37.61M
-$407K
-$969K
-$19.08M
-$41.14M
$4.65M
Net income attributable to common shareholders
-$737K
-$16.72M
-$37.61M
-$407K
-$969K
-$19.08M
-$41.14M
$4.65M
EBITDA
$4.64M
-$11.82M
-$31.88M
$6.02M
$5.57M
-$13.76M
-$35.75M
$8.64M
Basic earnings per share
$0.00
-$0.07
-$0.15
$0.00
$0.00
-$0.08
-$0.17
$0.02
Diluted earnings per share
$0.00
-$0.07
-$0.15
$0.00
$0.00
-$0.08
-$0.17
$0.02
Recent news
Company coverage with links to the original publishers.
A class action lawsuit has been filed against Ardelyx, Inc. alleging that the company made false and misleading statements regarding its commercial performance. The complaint claims Ardelyx failed to disclose increasing payer-related access barriers, stringent prior authorization requirements, and negative impacts on growth prospects for its drugs XPHOZAH and IBSRELA during the period from January 13, 2025 to August 6, 2026.
Rosen Law Firm reminds investors in Ardelyx, Inc. (NASDAQ: ARDX) who purchased stock between January 13, 2025 and August 6, 2026 of the November 16, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided false and misleading statements about commercial performance and growth prospects for its drugs XPHOZAH and IBSRELA, while concealing material facts about payer access barriers, prior authorization requirements, and step edit requirements that hindered patient access.
A class action lawsuit has been filed against Ardelyx, Inc. alleging that the company made false and misleading statements regarding its commercial performance and growth prospects for drugs XPHOZAH and IBSRELA. The complaint claims Ardelyx failed to disclose increasing payer-related access barriers and stringent prior authorization requirements that negatively impacted patient access and commercial performance during the class period from January 13, 2025 to August 6, 2026.
Bronstein, Gewirtz & Grossman, LLC has announced multiple class action lawsuits against Kinross Gold Corporation, Ardelyx, Inc., and Bank of America Corporation for alleged securities fraud violations. Investors who purchased securities during specified periods are encouraged to seek recovery, with lead plaintiff deadlines ranging from November 2026 to January 2027.
Rosen Law Firm has issued deadline notices for securities class action lawsuits against Doximity, Inc. and Ardelyx, Inc., with a November 16, 2026 lead plaintiff deadline. The firm is also announcing a newly filed lawsuit against NVIDIA Corporation. Investors who purchased shares during specified class periods may be eligible for compensation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.